Marketing dimensions in the prescription pharmaceutical industry: a systematic literature review

The pharmaceutical market is experiencing significantly amplified research and development costs, as well as increasing price and other competitive pressures. This article presents a much-needed systematic review of the literature relevant to pharmaceutical marketing. The authors find that the order-of-entry effect is critical in the sector, but that both early- and late-entry strategies can be effective when coupled with the appropriate marketing strategies. Within this context, the present study reveals that promotion policy is the most relevant, followed by price policy, with product design policy surprisingly only third in importance. Distribution (place) is the least relevant in the pharmaceutical context. These findings are used to drive an agenda for future research in pharmaceutical marketing.

[1]  G. Kalyanaram,et al.  Order-of-Entry Effects on Consumer Memory and Judgment: An Information Integration Perspective , 1992 .

[2]  Stephen J. Hoch,et al.  Managing What Consumers Learn from Experience , 1989 .

[3]  Joshua P Cohen The new Dutch health insurance system and its implications for pharmaceutical innovation , 2007 .

[4]  Sandy Oliver,et al.  Integrating qualitative research with trials in systematic reviews , 2004, BMJ : British Medical Journal.

[5]  Daniel Hogan,et al.  The 30-Sec Sale: Using Thin-Slice Judgments to Evaluate Sales Effectiveness , 2006 .

[6]  R. Tallman,et al.  Relationships of physicians with pharmaceutical sales representatives and pharmaceutical companies: an exploratory study. , 1996, Health marketing quarterly.

[7]  Pierre Azoulay,et al.  Do Pharmaceutical Sales Respond to Scientific Evidence , 2002 .

[8]  J. R. Williams,et al.  Direct-to-consumer advertising of prescription drugs. , 1995, Journal of health care marketing.

[9]  Marcia Angell,et al.  The Truth About the Drug Companies , 2004 .

[10]  James J. Chrisman,et al.  Order of market entry, competitive strategy, and financial performance , 1995 .

[11]  Nicholas J. Ashill,et al.  Pharmaceutical marketing return‐on‐investment: a European perspective , 2007 .

[12]  R. Bond,et al.  Sales, Promotion and Product Dif-ferentiation in Two Prescription Drug Markets , 1977 .

[13]  Sridhar Narayanan,et al.  Return on Investment Implications for Pharmaceutical Promotional Expenditures: The Role of Marketing-Mix Interactions , 2004 .

[14]  J. Lexchin Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit Formulary. , 2009, Health policy.

[15]  Maarten C. W. Janssen,et al.  Early mover advantages: An empirical analysis of European mobile phone markets , 2008 .

[16]  R. Schmalensee Product Differentiation Advantages of Pioneering Brands , 1980 .

[17]  B. Wernerfelt,et al.  An Evaluation Cost Model of Consideration Sets , 1990 .

[18]  B. Mintzes,et al.  For and against: Direct to consumer advertising is medicalising normal human experience: For. , 2002, BMJ : British Medical Journal.

[19]  E. Berndt,et al.  Effects of Direct-to-Consumer Advertising on Medication Choice: The Case of Antidepressants , 2004 .

[20]  Mickey C. Smith Principles of pharmaceutical marketing , 1969 .

[21]  Kevin Lane Keller,et al.  MARKETING MANAGEMENT 12e , 2006 .

[22]  S. Hart,et al.  Marketing Strategy and Planning in the UK Pharmaceutical Industry: Some Preliminary Findings , 1990 .

[23]  W. T. Robinson,et al.  Note: The Impact of Leadtime and Years of Competitive Rivalry on Pioneer Market Share Advantages , 1994 .

[24]  김정남 고객과 지식 Marketing , 2003 .

[25]  Preventing childhood obesity by reducing consumption of carbonated drinks: cluster randomised controlled trial , 2004, BMJ : British Medical Journal.

[26]  S. Tagg,et al.  A grounded theory of doctors' information search behaviour. Implications for information provision, pharmaceutical market entry and development , 2007 .

[27]  Venkatesh Shankar,et al.  Pioneers' Marketing Mix Reactions to Entry in Different Competitive Game Structures: Theoretical Analysis and Empirical Illustration , 1997 .

[28]  A. Po A PRACTICAL GUIDE TO UNDERTAKING A SYSTEMATIC OVERVIEW , 1997 .

[29]  R. Cooper,et al.  Major new products: What distinguishes the winners in the chemical industry? , 1993 .

[30]  Richard Staelin,et al.  Environment, Market Share, and Market Power , 1990 .

[31]  K. Boulding,et al.  Barriers to New Competition: Their Character and Consequences in Manufacturing Industries. , 1957 .

[32]  Gerard J. Tellis,et al.  First to Market, First to Fail? Real Causes of Enduring Market Leadership , 2006 .

[33]  Elisabeth Honka,et al.  The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review. , 2005, Yale journal of health policy, law, and ethics.

[34]  Lisa C . Troy,et al.  Order of Entry and Business Performance: An Empirical Synthesis and Reexamination , 1995 .

[35]  J. Rizzo,et al.  Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs* , 1999, The Journal of Law and Economics.

[36]  N. A. Nichols Scientific management at Merck: An interview with CFO Judy Lewent , 1994 .

[37]  Gilbert A. Churchill,et al.  The Determinants of Salesperson Performance: A Meta-Analysis , 1985 .

[38]  The order of entry effect in prescription (Rx) and over‐the‐counter (OTC) pharmaceutical drugs , 2008 .

[39]  J. Lattin,et al.  Investigating the relationship between time in market and pioneering advantage , 1994 .

[40]  David H. Reiley,et al.  The Roles of Marketing, Product Quality and Price Competition in the Growth and Composition of the U.S. Anti-Ulcer Drug Industry , 1994 .

[41]  B. Glitz The focus group technique in library research: an introduction. , 1997, Bulletin of the Medical Library Association.

[42]  M. Lambkin Order of entry and performance in new markets , 1988 .

[43]  C. Simon,et al.  Making more of pharma's sales force: pharmaceutical companies have lost their focus on doctors. The key to higher sales is regaining it , 2002 .

[44]  F. Mosteller,et al.  A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. , 1992, JAMA.

[45]  Füsun F. Gönül,et al.  Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior , 2001 .

[46]  Glen L. Urban,et al.  Market Share Rewards to Pioneering Brands: An Empirical Analysis and Strategic Implications , 2015 .

[47]  Yun Jung Lee,et al.  Value‐driven consumer e‐health information search behavior , 2007 .

[48]  Peter R.J. Trim,et al.  A new product launch strategy (NPLS) model for pharmaceutical companies , 2005 .

[49]  C. Fornell,et al.  Sources of Market Pioneer Advantages in Consumer Goods Industries , 1985 .

[50]  Z. Griliches,et al.  Characteristics of demand for pharmaceutical products: an examination of four cephalosporins. , 1997, The Rand journal of economics.

[51]  Joel B. Cohen,et al.  Alternative Models of Categorization: Toward a Contingent Processing Framework , 1987 .

[52]  Jos Kleijnen,et al.  The comprehensiveness of Medline and Embase computer searches , 1992, Pharmaceutisch Weekblad.

[53]  D. Dogramatzis Pharmaceutical Marketing: A Practical Guide , 2001 .

[54]  M. Petticrew,et al.  Systematic Reviews in the Social Sciences , 2006 .

[55]  P. Kotler A Generic Concept of Marketing , 1972 .

[56]  G. Jin,et al.  The Effects of Direct-to-Consumer Advertising in the Prescription Drug Markets , 2002 .

[57]  R Hartley,et al.  Scientific versus commercial sources of influence on the prescribing behavior of physicians. , 1982, The American journal of medicine.

[58]  Barton A. Weitz,et al.  The SOCO Scale: A measure of the customer orientation of salespeople. , 1982 .

[59]  Maija Renko,et al.  Critical innovation characteristics influencing the acceptability of a new pharmaceutical product format , 2007 .

[60]  Stefan Stremersch,et al.  Health and marketing: The emergence of a new field of research ☆ , 2008 .

[61]  W. Mitchell Whether and When? Probability and Timing of Incumbents' Entry into Emerging Industrial Subfields , 1989 .

[62]  David M Levinson,et al.  First Mover Advantages , 2011 .

[63]  J. Avorn,et al.  Physician motivations for nonscientific drug prescribing. , 1989, Social science & medicine.

[64]  Sriram Venkataraman,et al.  The Debate on Influencing Doctors’ Decisions: Are Drug Characteristics the Missing Link? , 2007, Manag. Sci..

[65]  Jaap E. Wieringa,et al.  Modeling the effects of pharmaceutical marketing , 2010 .

[66]  Natalie Mizik,et al.  Are Physicians "Easy Marks"? Quantifying the Effects of Detailing and Sampling on New Prescriptions , 2004, Manag. Sci..

[67]  P. Berthon,et al.  Communication in the salesperson/customer dyad: an empirical investigation , 1998 .

[68]  Roland Soong,et al.  ‘Ask Your Doctor!’ Measuring the effect of direct-to-consumer communications in the world’s largest healthcare market , 2004 .

[69]  W P McKinney,et al.  Pharmaceutical representatives in academic medical centers , 1990, Journal of General Internal Medicine.

[70]  J. Dawes,et al.  What is Differentiation and How Does it Work ? , 2001 .

[71]  Joel Lexchin,et al.  The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States , 2008, PLoS medicine.

[72]  Tammo H. A. Bijmolt,et al.  Generalizations on the effectiveness of pharmaceutical promotional expenditures , 2008 .

[73]  D. Vakratsas,et al.  A dual-market diffusion model for a new prescription pharmaceutical , 2008 .

[74]  G. Robert,et al.  Diffusion of innovations in service organizations: systematic review and recommendations. , 2004, The Milbank quarterly.

[75]  G. Kalyanaram,et al.  Order of Market Entry: Established Empirical Generalizations, Emerging Empirical Generalizations, and Future Research , 1995 .

[76]  Gregory S. Carpenter,et al.  Late Mover Advantage: How Innovative Late Entrants Outsell Pioneers: , 1998 .

[77]  G. Lilien,et al.  The timing of competitive market entry: an exploratory study of new industrial products , 1990 .

[78]  Pradeep K. Chintagunta,et al.  Responsiveness of Physician Prescription Behavior to Salesforce Effort: An Individual Level Analysis , 2004 .

[79]  Ira Horowitz,et al.  New-product success in the pharmaceutical industry: how many bites at the cherry? , 2005 .

[80]  D. Forbes Principles of Pharmaceutical Marketing , 1975 .

[81]  Robert A. Peterson,et al.  First-Mover Advantage: A Synthesis, Conceptual Framework, and Research Propositions , 1992 .

[82]  Leonard J. Parsons,et al.  Analysis of Sales Call Effectiveness , 1981 .

[83]  N. Carroll,et al.  Consumer responses to direct to consumer prescription drug advertising , 2007 .

[84]  G. Kalyanaram,et al.  Dynamic Effects of the Order of Entry on Market Share, Trial Penetration, and Repeat Purchases for Frequently Purchased Consumer Goods , 1992 .

[85]  Stefan Stremersch,et al.  Marketing of the Life Sciences: A New Framework and Research Agenda for a Nascent Field , 2009 .

[86]  Morgan P. Miles,et al.  A research note on market creation in the pharmaceutical industry , 2011 .

[87]  W. S. Comanor,et al.  The political economy of the pharmaceutical industry. , 1986, Journal of economic literature.

[88]  Vivek Madupu,et al.  How did you find your physician , 2009 .

[89]  Jennifer S. Lin,et al.  Using Existing Systematic Reviews in Complex Systematic Reviews , 2008, Annals of Internal Medicine.

[90]  D. Wong-Rieger Should Canada allow direct-to-consumer advertising of prescription drugs?: yes. , 2009, Canadian family physician Medecin de famille canadien.

[91]  S. Tett,et al.  Prescription drug samples – does this marketing strategy counteract policies for quality use of medicines? , 2003, Journal of clinical pharmacy and therapeutics.

[92]  K. Shojania,et al.  How Quickly Do Systematic Reviews Go Out of Date? A Survival Analysis , 2007, Annals of Internal Medicine.

[93]  Hubert Gatignon,et al.  Order of Entry as a Moderator of the Effect of the Marketing Mix on Market Share , 1996 .

[94]  K. Leffler,et al.  Persuasion or Information? The Economics of Prescription Drug Advertising , 1981, The Journal of Law and Economics.

[95]  Ambar G. Rao,et al.  Bayesian Estimation and Control of Detailing Effort in a Repeat Purchase Diffusion Environment , 1981 .

[96]  G. Tellis,et al.  Pioneer Advantage: Marketing Logic or Marketing Legend? , 1993 .

[97]  Andrea Coscelli,et al.  The Importance of Doctors' and Patients' Preferences in the Prescription Decision , 2003 .

[98]  Prof. Dr. Wieland Kiess,et al.  Gesundheitsreformen in Deutschland , 2007, Kinder- und Jugendmedizin.

[99]  F Davidoff,et al.  Systematic Reviews: Critical Links in the Great Chain of Evidence , 1997, Annals of Internal Medicine.

[100]  Andrew T. Ching,et al.  Understanding Firm, Physician and Consumer Choice Behavior in the Pharmaceutical Industry , 2005 .

[101]  David H. Reiley,et al.  The Roles of Marketing, Product Quality and Price Competition in the Growth and Composition of the U.S. Anti-Ulcer Drug Industry , 1994 .

[102]  David Moher,et al.  Epidemiology and Reporting Characteristics of Systematic Reviews , 2007, PLoS medicine.

[103]  Jesús Gutiérrez-Cillán,et al.  Order, positioning, scope and outcomes of market entry , 2008 .

[104]  L. de Chernatony,et al.  Winning Hearts and Minds: Business-to-Business Branding and the Role of the Salesperson , 2007 .

[105]  Min Ding,et al.  A Dynamic Competitive Forecasting Model Incorporating Dyadic Decision Making , 2008, Manag. Sci..

[106]  G. Kalyanaram The endogenous modeling of the effect of direct‐to‐consumer advertising in prescription drugs , 2009 .

[107]  B. Jönsson Flat or monotonic pricing of pharmaceuticals: practice and consequences , 2001, The European Journal of Health Economics (HEPAC).

[108]  M. Hollon Direct-to-consumer marketing of prescription drugs: creating consumer demand. , 1999, JAMA.

[109]  Jennifer Rice Are HMO physicians more price sensitive in prescribing brand‐name drugs? , 2009 .